Millennium Management
RLMD icon

Millennium Management’s Relmada Therapeutics RLMD Stock Holding History

Millennium Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.2M Buy
3,907,265
+2,234,248
+134% +$10.6M 0.01% 1295
2025
Q4 		$8.08M Buy
+1,673,017
New +$5.61M ﹤0.01% 2502
2024
Q4 		– Sell
-561,826
Closed -$1.82M – 6391
2024
Q3 		$1.82M Buy
561,826
+497,469
+773% +$1.61M ﹤0.01% 3780
2024
Q2 		$193K Sell
64,357
-277,093
-81% -$1M ﹤0.01% 5152
2024
Q1 		$1.59M Buy
341,450
+142,549
+72% +$687K ﹤0.01% 3926
2023
Q4 		$823K Sell
198,901
-45,300
-19% -$134K ﹤0.01% 4303
2023
Q3 		$733K Sell
244,201
-99,774
-29% -$296K ﹤0.01% 4403
2023
Q2 		$846K Buy
343,975
+141,647
+70% +$392K ﹤0.01% 4173
2023
Q1 		$457K Sell
202,328
-859,446
-81% -$2.96M ﹤0.01% 4662
2022
Q4 		$3.71M Buy
1,061,774
+1,042,044
+5,282% +$9.15M ﹤0.01% 3055
2022
Q3 		$730K Sell
19,730
-98,780
-83% -$2.74M ﹤0.01% 4613
2022
Q2 		$2.25M Sell
118,510
-161,079
-58% -$3.51M ﹤0.01% 3585
2022
Q1 		$7.55M Sell
279,589
-274,403
-50% -$5.67M ﹤0.01% 2473
2021
Q4 		$12.5M Buy
553,992
+299,412
+118% +$6.66M 0.01% 1905
2021
Q3 		$6.67M Buy
254,580
+238,351
+1,469% +$6.38M ﹤0.01% 2544
2021
Q2 		$519K Buy
16,229
+9,860
+155% +$342K ﹤0.01% 5273
2021
Q1 		$224K Sell
6,369
-18,561
-74% -$649K ﹤0.01% 5431
2020
Q4 		$800K Buy
+24,930
New +$857K ﹤0.01% 3878
2020
Q3 		– Sell
-43,328
Closed -$1.67M – 4759
2020
Q2 		$1.94M Buy
43,328
+4,905
+13% +$207K ﹤0.01% 2562
2020
Q1 		$1.31M Buy
38,423
+15,222
+66% +$614K ﹤0.01% 2292
2019
Q4 		$905K Buy
+23,201
New +$705K ﹤0.01% 3055

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Millennium Management's RLMD Position: Q1 2026 in Review

Millennium Management increased its Relmada Therapeutics (RLMD) stake by 134% in Q1 2026, buying an estimated $10.6M and bringing the position to 3,907,265 shares worth $27.2M. The position accounts for 0.01% of the portfolio, ranked #1295.

Millennium Management first reported a position in RLMD in Q4 2019 and has held it in 21 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Millennium Management held 3,907,265 shares of Relmada Therapeutics worth $27.2M as of Q1 2026.
  • Millennium Management bought 2,234,248 Relmada Therapeutics shares in Q1 2026, an estimated $10.6M.
  • Relmada Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1295 holding.
  • Millennium Management first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 21 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.